← Back to Search

Anti-parasitic agent

Treated eyes for Eyelash Mites

Phase 1

Waitlist Available

Research Sponsored by Helm Vision Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Inclusion Criteria:Voluntary participation of subjects with moderate to dense sleeves with no allergy to ivermectin and the ability to keep follow-up appointments.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up each patient will be followed for 6 months

Awards & highlights

Study Summary

This trial will test whether ivermectin cream can help get rid of Demodex infestation on the eyelashes.

Eligible Conditions

Eyelash Mites

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ each patient will be followed for 6 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~each patient will be followed for 6 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and each patient will be followed for 6 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparative density of sleeves

Secondary outcome measures

Comparative assessment of tear osmolarity between treated and untreated eyes

Side effects data

From 2009 Phase 2 trial • 264 Patients • NCT00994422

Excoriation

100%

80%

60%

40%

20%

Study treatment Arm

0.5% Ivermectin

Placebo (Vehicle Control)

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Treated eyesExperimental Treatment1 Intervention

All participants will have one eye randomly selected for treatment.

Group II: Untreated eyesActive Control1 Intervention

No treatment will be given to the control eye.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ivermectin

FDA approved

0 / 2Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Helm Vision GroupLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open recruitment slots for this clinical investigation?

"Affirmative. Data posted to clinicaltrials.gov testifies that this medical trial, first released on August 24th 2021, is actively enrolling participants. The research team needs 20 people at 1 site in order for the study to be successful."

Answered by AI

How many applicants are being considered for this experiment?

"Affirmative. According to the information hosted on clinicaltrials.gov, this trial initiated recruitment on August 24th 2021 and is currently actively searching for 20 participants at 1 site. It was last updated on January 20th 2022."

Answered by AI

Has the Food and Drug Administration given its stamp of approval to Treated eyes?

"Our team assesses the safety of this experimental treatment to be a score 1, as it is only at Phase 1. This means there are limited data regarding its efficacy and safety."

Answered by AI

Recent research and studies

CorneaJournal

Efficacy of Topical Ivermectin 1% in the Treatment of Demodex Blepharitis

Choi, Young, Youngsub Eom, Eun Gyu Yoon, Jong Suk Song, Il-Hwan Kim, and Hyo Myung Kim. 2021. “Efficacy of Topical Ivermectin 1% in the Treatment of Demodex Blepharitis”. Cornea. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ico.0000000000002802.

clinicaltrials.govStudy

Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%

Craig J. Helm 2021. "Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05213585.

All > Ivermectin